Efficacy of Combined Treatment with Metformin, Englitazone, Polyethylene Glycol Loxenatide, and Exercise Therapy in Patients with Obese Type 2 Diabetes
LI Pengyang, DU Xin, CHEN Changlong
Departments of Internal Three,the First People's Hospital of Wancheng District, Nanyang City, Henan Province, Nanyang Henan 473001
Abstract：【Objective】To explore the clinical efficacy of a combination treatment of metformin, empagliflozin, pegylated liraglutide and exercise therapy in the treatment of obese type 2 diabetes. 【Methods】A total of 112 obese type 2 diabetes patients admitted to our hospital from October 2020 to October 2023 were selected and divided into groups by the ball-picking method (odd numbers assigned to the control group and even numbers to the observation group), with 56 cases in each group. The control group was treated with metformin, empagliflozin combined with exercise therapy, while the observation group was treated with pegylated liraglutide in addition to treatment of the control group. The glycolipid metabolism indicators, pancreatic β-cell function, and carotid atherosclerosis indicators were compared before and after treatment in both groups. 【Results】After treatment, the levels of fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the control group, while the level of high-density lipoprotein cholesterol (HDL-C) was higher than that in the control group, and the differences were statistically significant (P<0.05). The pancreatic β-cell function index (HOMA-β) in the observation group was higher than that in the control group, and the insulin resistance index (HOMA-IR) was lower than that in the control group, and the differences were statistically significant (P<0.05). The carotid intima-media thickness (CIMT) and pulse wave velocity (PWV) in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). 【Conclusion】The combination of metformin, empagliflozin, pegylated liraglutide and exercise therapy in the treatment of obese type 2 diabetes patients can significantly improve glycolipid metabolism, enhance pancreatic β-cell function, and reduce atherosclerosis indicators.
李鹏阳, 杜欣, 陈长龙. 二甲双胍、恩格列净、聚乙二醇洛塞那肽联合运动疗法治疗肥胖2型糖尿病患者的疗效[J]. 医学临床研究, 2025, 42(6): 962-965.
LI Pengyang, DU Xin, CHEN Changlong. Efficacy of Combined Treatment with Metformin, Englitazone, Polyethylene Glycol Loxenatide, and Exercise Therapy in Patients with Obese Type 2 Diabetes. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 962-965.
2025, Vol. 42 
